Thank you for your interest in our facility. Our Integrative Cancer Treatment & Research Center (ICT-RC) is located in the Subic Bay, Philippines, and can serve as your best integrative treatment option in Asia, and most cost-effective option worldwide.
We specialize in personalized cancer immunotherapy: using modalities in order to specifically attack your cancer, thus the better your chances are at success and recovery.
Contact us directly at: +63-917-814-3443
We provide compassionate treatments for cancer using:
- Dendritic Cell Therapy
- Cancer Vaccines
- Tumor infiltrating lymphocytes (TILs) vaccines
- Natural Killer-like Cell vaccines
- CAR-T Cell Therapy
- Nutritional IV’s (high-dose vitamin C)
- Immune-stimulating herbal medicines
We use the patient’s own Dendritic Cells, along with the patient’s own tumor lysate and/or synthetic peptides (WT1-I, WT1-II, MUC1, and others), on an immediate basis. With these and other materials, we reprogram the patient’s immune cells outside the body to form Dendritic Cells, expose these activated cells to the cancer’s peptides, and re-infuse the vaccines back into the patient to stimulate a targeted immune response.
Additional immunotherapy treatments (PD-L1 inhibitors, etc.) may also be offered.
Costs of Targeted Immunotherapy Treatments Worldwide Vary
We may include:
- Nutritional IVs and other natural therapies and enzymes specifically to boost the immune system, and help prevent metastasis
- Vaccines activated against each peptide/tumor lysate
- Each vaccine is made individually and specifically for the patient
- Each vaccine is made as needed
- Each vaccine is made using the patient’s own blood or apheresis material
- Each vaccine is made using the patient’s own processed tumor cells and/or synthetic peptides, specifically made
- Each vaccine made is a time-consuming and labor-intensive process
To find out more or enroll in a study, please send us an email.
See our FAQ page for more information.
We hope that we may serve as an additional/adjunctive option in your treatment process.
Bladder cancer was the first indication for which an immunotherapy was granted approval by the Food and Drug Administration (FDA) in 1990.
Malignant brain tumors are relatively rare but very serious form of cancer. Immunotherapy is showing significant promise where other approaches have failed.
By far, the most significant cause of cervical cancer, as well as other ano-genital cancers, is infection with a virus—the human papillomavirus (HPV).
Colon cancer is the third most common type of cancer among both men and women in the United States, and is the second most deadly.
While many different types of cancer can occur in the head and neck, squamous cell carcinoma in the most common cancer of the head and neck.
About 9 out of every 10 kidney cancers are renal cell carcinoma cancers that form in the lining of the tubules inside the kidney.
When diagnosed early, liver cancer can be treated successfully with surgery, but liver donors are rare and few treatment options exist for patients with advanced disease.
In the U.S., lung cancer is by far the leading cause of cancer-related deaths among both men and women; causing more deaths annually than breast, prostate, and colon cancer combined.
Melanoma accounts for the majority of skin cancer-related deaths. Over the past few years, immunotherapy has dramatically changed the landscape of melanoma treatment.
Myeloma, also referred to as plasma cell myeloma, is a cancer that originates in plasma cells, a type of white blood cell that make antibodies.
Pancreatic cancer is the most lethal cancer and new therapies are urgently needed to impact pancreatic cancer treatment and to extend and save pancreatic cancer patients’ lives.
Prostate cancer is the second most common cancer in men worldwide, and the eighth leading cause of cancer-related death.
Stomach cancer is the fifth most common diagnosis in cancer, and it is the third most deadly, with nearly 725,000 deaths.
Integrative Cancer Treatment & Research Center
Subic Bay – Olongapo City,
*Immunotherapy results may vary from patient to patient.